Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Inex Plans Complete Spin-Out Into Tekmira In September

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Previous spin-out Protiva has filed suit to stop the firm from moving almost all of its assets into a new company.

You may also be interested in...



Alnylam Seeks To Advance RNAi Further With Inex Delivery Technology

There is an "open invitation" to companies and academia to partner with Inex on RNAi therapies, Inex CEO tells "The Pink Sheet" DAILY.

Alnylam Seeks To Advance RNAi Further With Inex Delivery Technology

There is an "open invitation" to companies and academia to partner with Inex on RNAi therapies, Inex CEO tells "The Pink Sheet" DAILY.

Inex Restructures: COO Is Timothy Ruane, Senior Execs Depart

Inex is shedding 60% of its workforce in a cost-cutting move aimed at reducing cash burn to under $1 mil. a month. CEO David Main and senior execs depart under reorganization, the second since an advisory committee’s unfavorable recommendation for Inex’ oncologic Marqibo.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS064543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By